Oculis Holding AG (OCS) Short-term Investments (2021 - 2026)
Oculis Holding AG (OCS) posted quarterly Short-term Investments of $201.1 million for Q1 2026, up 48.13% year-over-year from $135.8 million in Q1 2025, and up 22.05% quarter-over-quarter from $164.8 million in Q4 2025.
Analysis
Oculis Holding AG (OCS) Short-term Investments (2021 - 2026) Analysis & Trends
Oculis Holding AG's Short-term Investments history runs 4 years deep, the most recent figure standing at $201.1 million for Q1 2026.
- In Q1 2026, Short-term Investments rose 48.13% year-over-year to $201.1 million; the TTM figure through Mar 2026 stood at $201.1 million (up 48.13% YoY), while the FY2025 annual figure was $158.8 million, up 96.92% from the prior year.
- Short-term Investments for Q1 2026 stood at $201.1 million, up from $164.8 million in the prior quarter.
- The five-year high for Short-term Investments was $201.1 million in Q1 2026, with the low at -$85.9 million in Q3 2023.
- The 4-year median for Short-term Investments is $81.5 million (2024), against an average of $68.4 million.
- The sharpest annual moves came in 2024 and 2025: Short-term Investments surged 232.65% in 2024, then surged 41.63% in 2025.
- Oculis Holding AG's Short-term Investments stood at -$61.1 million in 2023, then soared by 232.65% to $81.0 million in 2024, then soared by 103.41% to $164.8 million in 2025, then increased by 22.05% to $201.1 million in 2026.
- Business Quant data shows OCS's Short-term Investments at $201.1 million in Q1 2026, $164.8 million in Q4 2025, and $123.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 210.93 Mn |
| Mar 31, 2026 | 201.09 Mn |
| Dec 31, 2025 | 164.76 Mn |
| Sep 30, 2025 | 123.44 Mn |
| Jun 30, 2025 | 116.00 Mn |
| Mar 31, 2025 | 135.76 Mn |
| Dec 31, 2024 | 81.00 Mn |
| Sep 30, 2024 | 80.61 Mn |
| Jun 30, 2024 | 81.91 Mn |
| Mar 31, 2024 | 63.67 Mn |
| Dec 31, 2023 | -61.06 Mn |
| Sep 30, 2023 | -85.90 Mn |
| Jun 30, 2023 | -80.16 Mn |
| Dec 31, 2022 | 51,901.10 |
| Dec 31, 2021 | 56,394.11 |